USPTO Director Announces He Will Determine IPR AND PGR Proceeding

The U.S. patent world loves a procedural update almost as much as it loves arguing about what a “reasonable likelihood” really means. In October 2025, the USPTO delivered one of the biggest procedure shakeups in years: the Director announced that he, not a PTAB merits panel, would determine whether inter partes review (IPR) and post-grant review (PGR) proceedings should be instituted. For patent owners, petitioners, litigators, and anyone else who has ever spent a suspiciously large amount of time staring at a PTAB docket, this was not a minor clerical tweak. It was a power shift.

At a high level, the move pulls institution authority back to the top of the agency. The USPTO framed that change as a return to the statute, a way to improve consistency, and a method for avoiding the perception that the same adjudicatory body was effectively deciding whether to create more work for itself. Critics, however, saw a different issue: more centralization, less transparency, and a real possibility that summary notices could make it harder to understand why some petitions live and others die.

Either way, one thing is clear: if your patent strategy still assumes the old PTAB institution playbook, it is already collecting dust.

What Are IPR and PGR, and Why Should Anyone Care?

IPR and PGR are trial-like proceedings before the Patent Trial and Appeal Board, or PTAB. They allow third parties to challenge issued patent claims without going straight to a full-blown district court slugfest. In theory, these proceedings offer a faster, more technical forum for addressing patent validity. In practice, they are often a central feature of high-stakes patent disputes, especially in technology, electronics, life sciences, and pharmaceuticals.

IPR in plain English

Inter partes review is the better-known cousin. It generally allows a challenger to attack an issued patent using patents or printed publications. IPR has become a standard defensive tool for accused infringers, especially where they believe the patent should never have survived examination in the first place.

PGR in plain English

Post-grant review is broader in some ways, but it is available only during a narrower time window after patent issuance. PGR can raise more kinds of invalidity arguments than IPR, which makes it a potent weapon when the timing works. Think of IPR as the established veteran and PGR as the versatile specialist who only shows up if you call early enough.

Because institution is the gatekeeping stage, the person making that decision matters a lot. If a petition is denied, the merits never get a full PTAB trial. That is why the Director’s announcement landed with the subtlety of a dropped anvil.

What Exactly Changed at the USPTO?

To understand the announcement, it helps to look at 2025 as a two-step process rather than a single event.

First, in March 2025, the USPTO introduced an interim process for PTAB workload management. That system split institution questions into two buckets: discretionary considerations on one side, and merits plus other non-discretionary issues on the other. Under that framework, the Director took control of discretionary-denial decisions, while PTAB panels still handled the merits side in many cases.

Then came the bigger October 2025 move. The USPTO Director announced that he would determine whether to institute trials in all IPR and PGR proceedings. In other words, institution authority no longer stopped halfway at the Director’s desk. It moved there fully.

That means the Director now reviews discretionary considerations, merits, and non-discretionary issues together, in consultation with at least three PTAB judges. If institution is granted, the case is then referred to a PTAB panel to conduct the trial. So the PTAB still runs the trial after institution, but it no longer owns the threshold up-or-down decision in the same way it did for years.

The practical features of the new process

The change did not rewrite everything. The briefing schedule remains the same. The due dates remain the same. The conduct of the AIA trial after institution remains the same. What changed is who makes the threshold call and how that decision is often delivered.

And here is the part that made many practitioners sit up a little straighter: most institution outcomes are expected to come in the form of a summary notice. Translation: a petition may be instituted or denied without a detailed, full-length opinion explaining every stop on the legal road trip.

That might sound efficient. It also might sound like trying to solve a puzzle after someone threw away the picture on the box.

Why the USPTO Says the Director Needed to Take Over

The USPTO’s stated rationale was not shy. The agency emphasized that the America Invents Act places institution authority in the Director. While delegation was legally possible, the October 2025 materials argued that the Director retained full and concurrent authority all along.

The agency also raised concerns about structure and perception. According to the Director’s open letter, the old delegated model created worries that PTAB judges could appear to be “filling their own docket,” even if that concern was more about optics than actual misconduct. The Director also suggested that the interim bifurcated system had contributed to unusually high institution rates in referred cases, which in his view weakened confidence in the threshold screening function.

From the agency’s perspective, centralizing institution decisions improves accountability, better aligns practice with the statute, and separates the body that decides whether a case should proceed from the body that tries the case once it does. That is the clean-government version of the story.

Why Some Patent Lawyers Are Nervous

The pushback is easy to understand. PTAB practice has long depended on detailed institution decisions that gave parties insight into the agency’s reasoning. Even when practitioners did not like the outcome, they could usually see how the Board got there. Summary notices change that dynamic.

If a denial comes with little or no explanation, petitioners may struggle to assess whether the problem was weak prior art, an avoidable procedural defect, discretionary denial, real-party-in-interest issues, timing, parallel litigation, or something else entirely. Patent owners may win the immediate battle but still lack a road map for how the Office is weighing arguments across industries and fact patterns.

In short, centralization may increase accountability at the top while decreasing visibility at the ground level. That tension is likely to define debates about the new institution framework for a while.

What the New Institution Process Means for Petitioners

1. Front-load everything

If there was ever a time to file a “good enough” petition and hope the panel would sort things out later, that time is looking increasingly prehistoric. Petitioners now need cleaner records, tighter briefing, stronger claim charts, and fewer loose threads. The Director-level institution model rewards discipline and punishes wishful thinking.

2. Timing matters more than ever

Patent owners gained traction in 2025 with arguments tied to “settled expectations,” especially where patents had been in force for years or where petitioners appeared to have known about the patent long before filing. That means waiting until litigation pressure becomes unbearable may be a dangerous strategy. In some industries, especially pharma and medical technology, delay may now look like a self-inflicted wound wearing a business-casual outfit.

3. Expect tougher procedural scrutiny

The broader 2025 PTAB environment suggests that institution is not becoming more forgiving. Real-party-in-interest issues drew renewed attention. Prior-art rules in IPR also tightened, particularly regarding attempts to rely on applicant-admitted prior art to fill missing claim limitations. Petitioners should assume that threshold compliance arguments are no longer background noise. They are part of the main event.

What the New Institution Process Means for Patent Owners

1. Discretionary arguments have real bite

Patent owners should not treat discretionary denial briefing as decorative garnish. In the current environment, arguments about timing, parallel litigation, prior adjudications, settled expectations, and case-specific fairness can matter at the threshold stage. The Director has signaled that institution is not a pure merits exercise.

2. Institution defense starts early

The strongest patent-owner response is no longer just “their art is bad.” It is often a layered response: their art is bad, their timing is bad, their record is incomplete, the case overlaps with another forum, the petition raises fairness concerns, and by the way, the procedural rules still exist for a reason.

3. A thin notice can still be a big win

Some patent owners may be frustrated by denials that do not provide detailed reasoning. But from a practical standpoint, a summary notice denying institution still gets the most important job done: it keeps the patent out of trial before the PTAB. Sometimes brevity is not just the soul of wit. Sometimes it is the soul of survival.

Specific Examples That Show the Shift Is Real

The new framework did not stay theoretical for long. By late October and early November 2025, practitioners were already discussing the first Director-level institution outcomes. Early reporting noted that the first decision under the new process denied thirteen unrelated IPRs in a single summary-style notice, with no detailed explanation attached. That was a loud signal that the Office intended to use the summary-notice model in earnest, not just keep it in a policy memo display case.

Earlier in 2025, the PTAB ecosystem had already shown that discretionary denial could reshape outcomes. In the iRhythm and Dabico decisions, institution was denied based on “settled expectations,” pointing to the age of the challenged patents and, in one instance, the petitioner’s longstanding awareness of the patent. Those decisions matter because they illustrate how institution analysis had already expanded beyond a classic prior-art merits fight. The October announcement did not create that trend from scratch, but it made the Director the unmistakable center of it.

Put differently, the new system does not merely change the person signing the paperwork. It changes the strategic atmosphere around the paperwork.

The Bigger Policy Question: Is This Better?

There are two serious arguments here, and both deserve more than eye-rolling.

The first argument is that institution authority always belonged with the Director as a matter of statute, so bringing it back there improves legitimacy. It also separates the institution gatekeeper from the panel that conducts the trial, which may reduce concerns about incentives and institutional bias.

The second argument is that concentrated authority plus summary notices may reduce transparency, increase unpredictability, and make meaningful rehearing requests harder to frame. If parties do not know why a petition was denied, they may have trouble correcting course in future filings or challenging mistakes in the current one.

Both can be true at once. The new framework may be more centralized and more faithful to the USPTO’s reading of the statute, while also being less transparent in day-to-day practice. Patent lawyers, in other words, may soon be arguing not over whether the system changed, but over which tradeoff hurts more.

What Companies and Counsel Should Do Now

For petitioners

Audit timing before filing. Tighten the real-party-in-interest analysis. Make sure every claim element is supported exactly where the rules require. Assume discretionary arguments will be taken seriously. Treat the petition as though you may never get a detailed explanation if you lose.

For patent owners

Do not leave threshold arguments on the table. Develop a record on delay, prior proceedings, related litigation, public-interest concerns, and any fact that supports discretionary denial. If the petitioner’s story has gaps, this is not the year to be shy about pointing them out.

For in-house teams

Coordinate PTAB and district-court strategy earlier. The gap between “litigation position” and “institution position” is shrinking. The facts that help in one forum may now shape whether the PTAB doors open at all.

Experience From the Field: What Practitioners Are Running Into Right Now

One of the most noticeable experiences practitioners report under the evolving 2025-2026 framework is that the institution stage feels less like a familiar administrative checkpoint and more like a high-stakes audition with the curtain already half down. Under the old model, parties often believed that a well-developed merits panel would explain itself in detail. That expectation created a certain style of lawyering: parties still worked hard, of course, but there was comfort in knowing the institution decision would usually map the strengths and weaknesses of the petition in a fairly detailed way.

That comfort is fading. Petitioners now have to prepare for the possibility that a denial may arrive with very little explanation. The result is a different kind of drafting behavior. Lawyers are front-loading arguments, cleaning up declarations earlier, tightening real-party-in-interest analysis before filing instead of after a challenge, and treating institution briefing as the only guaranteed chance to educate the decision-maker. There is less appetite for “we can clarify that later.” Later may never show up.

Patent owners are having a different, but equally intense, experience. They are learning that discretionary denial arguments are no longer side quests. A few years ago, some patent owners treated them as worthwhile but secondary. Now those arguments often sit near the top of the outline. Counsel are spending more time developing facts about when the petitioner knew of the patent, what happened in parallel litigation, whether another tribunal has already considered overlapping issues, and whether the age of the patent or the surrounding business context supports settled expectations. The tone has changed from “we might mention this” to “we had better build this properly.”

Another practical experience is uncertainty around signaling. In a detailed institution opinion, practitioners could often spot what mattered to the Board. Was the weak point the obviousness rationale? A missing claim limitation? A defective priority argument? A problem under Fintiv or another discretionary doctrine? Summary notices do not offer that same visibility. That creates strategic anxiety on both sides. Petitioners wonder how to improve the next filing. Patent owners wonder which arguments carried the day and whether they should invest in the same mix next time. The process can feel a bit like taking a very expensive test and receiving back only the word “no.”

There is also a noticeable human factor. Clients ask more threshold-stage questions now because the institution phase itself has become a bigger boardroom issue. General counsel want to know not just whether the patent challenge is strong, but whether the Office is likely to hear it at all. Business teams want earlier go-or-no-go recommendations. Budgeting discussions happen sooner. In-house counsel are pushing outside teams to connect district court developments, PTAB timing, prior adjudications, and public-interest narratives into one coordinated strategy rather than several loosely related memos.

Perhaps the clearest practical experience is this: nobody treats institution as routine anymore. Petitioners see a narrower gate. Patent owners see a more meaningful opportunity to keep it closed. And everyone involved understands that the Director’s announcement was not just a reshuffling of internal agency furniture. It changed the room.

Conclusion

The announcement that the USPTO Director will determine whether IPR and PGR proceedings move forward is one of the most consequential PTAB developments in recent memory. It centralizes authority, reinforces the importance of discretionary considerations, and raises the stakes of early-case strategy for both patent challengers and patent owners.

For supporters, the move restores statutory accountability and separates institution from trial. For critics, it risks creating a less transparent institution process, especially when summary notices replace full explanations. For everyone else trying to navigate the system, the takeaway is simpler: the threshold battle has become more important, more strategic, and less forgiving.

In patent law, procedure often looks boring until it starts deciding outcomes. This is one of those times.